Jeena Sikho Lifecare Limited Stock Price Today (NSE: JSLL)
Fundamental Score
Jeena Sikho Lifecare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Jeena Sikho Lifecare Limited share price today is ₹539.70, down 6.87% on NSE/BSE as of 30 March 2026. Jeena Sikho Lifecare Limited (JSLL) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹8.96K (Cr). The 52-week high for JSLL share price is ₹2450.00 and the 52-week low is ₹400.25. At a P/E ratio of 58.20x, JSLL is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 37.93% and a debt-to-equity ratio of 0.30.
Jeena Sikho Lifecare Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Jeena Sikho Lifecare Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Jeena Sikho Lifecare Share Price: A Financial Analysis
The pharmaceutical industry is currently witnessing a shift towards preventative healthcare and personalized medicine, creating opportunities for companies focused on holistic wellness solutions. This analysis examines the financial standing of Jeena Sikho Lifecare Limited, with a focus on its recent performance. The current Jeena Sikho Lifecare share price stands at ₹712.2999877929688, and understanding its underlying financial health is crucial for investors.
Currently, Jeena Sikho Lifecare Limited's Price-to-Earnings (PE) ratio is 58.2. This is a significant multiple, suggesting a premium valuation. A high PE could imply high growth expectations from the market. To benchmark this, it’s vital to consider the PE ratios of its peers. While a direct comparison is difficult without access to the peers' exact PE ratios at the time of this analysis, companies like
Mankind Pharma Ltd are generally perceived to have strong management teams. Assessing the quality of Jeena Sikho's management, their strategic decisions, and their track record will be crucial in justifying this valuation premium.A standout metric is Jeena Sikho Lifecare Limited's Return on Capital Employed (ROCE) of 50.24%. This indicates exceptional efficiency in generating profits from its capital. The high ROCE is a significant positive, suggesting a strong competitive advantage. A consistently high ROCE, sustained over time, can contribute significantly to building a strong economic moat, protecting the company's profitability from competitors. It demonstrates the company's ability to reinvest earnings at high rates, driving further growth.
This financial analysis is part of a more comprehensive, 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a detailed understanding of Jeena Sikho Lifecare's financial health. This analysis uses observational data regarding publicly available financial metrics. It is not a recommendation to buy, sell, or hold shares of Jeena Sikho Lifecare Limited. Further due diligence is advised before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jeena Sikho Lifecare Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JSLL across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (37.93%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (50.24%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (23.44%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (134.85%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (70.05%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (37.81% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (72.79% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.30)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (33.81x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (63.61%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 58.20x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-35.51% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-21.82 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 6.74%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Jeena Sikho Lifecare Limited Financial Statements
Comprehensive financial data for Jeena Sikho Lifecare Limited including income statement, balance sheet and cash flow
About JSLL (Jeena Sikho Lifecare Limited)
Jeena Sikho Lifecare Limited is a dynamic and rapidly evolving pharmaceutical company rooted in the ancient wisdom of Ayurveda. The company is primarily engaged in the development,... manufacturing, and distribution of a diverse portfolio of Ayurvedic formulations designed to promote holistic wellness and address a wide range of health concerns. From meticulously crafted herbal remedies to specialized dietary supplements, Jeena Sikho Lifecare is dedicated to leveraging the power of natural ingredients, sourced responsibly and processed with stringent quality control measures, to create effective and accessible healthcare solutions. The organization seeks to bridge the gap between traditional Ayurvedic practices and modern pharmaceutical standards. Beyond its product line, Jeena Sikho Lifecare is committed to delivering comprehensive healthcare services that complement its Ayurvedic offerings. The company operates a network of specialized clinics and healthcare facilities where experienced practitioners provide personalized consultations and customized treatment plans. These services encompass a variety of therapeutic modalities, including Panchakarma, a detoxifying and rejuvenating Ayurvedic treatment, as well as expert guidance on diet, lifestyle, and preventative care. Through this integrated approach, Jeena Sikho Lifecare aims to empower individuals to take control of their health and well-being, fostering a deeper understanding of the interconnectedness of mind, body, and spirit. Jeena Sikho Lifecare Limited distinguishes itself through a commitment to research and innovation, constantly exploring new applications of Ayurvedic principles and integrating them with cutting-edge scientific advancements. By investing in research and development, the company strives to enhance the efficacy and safety of its formulations, while also expanding its range of offerings to meet the evolving needs of the healthcare market. The company's goal is to solidify its position as a trusted provider of authentic and evidence-based Ayurvedic solutions, contributing to the promotion of natural and sustainable healthcare practices.
Company Details
Key Leadership
Corporate Events
JSLL Share Price: Frequently Asked Questions
What is the current share price of Jeena Sikho Lifecare Limited (JSLL)?
As of 30 Mar 2026, 12:03 pm IST, Jeena Sikho Lifecare Limited share price is ₹539.70. The JSLL stock has a market capitalisation of ₹8.96K (Cr) on NSE/BSE.
Is JSLL share price Overvalued or Undervalued?
JSLL share price is currently trading at a P/E ratio of 58.20x, compared to the industry average of 31.77x. Based on this relative valuation, the Jeena Sikho Lifecare Limited stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of JSLL share price?
The 52-week high of JSLL share price is ₹2450.00 and the 52-week low is ₹400.25. These values are updated daily from NSE/BSE price data.
What factors affect the Jeena Sikho Lifecare Limited share price?
Key factors influencing JSLL share price include quarterly earnings growth (Sales Growth: 70.05%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Jeena Sikho Lifecare Limited a good stock for long-term investment?
Jeena Sikho Lifecare Limited shows a 5-year Profit Growth of 72.79% and an ROE of 37.93%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.30 before investing in JSLL shares.
How does Jeena Sikho Lifecare Limited compare with its industry peers?
Jeena Sikho Lifecare Limited competes with major peers in the Pharmaceuticals. Investors should compare JSLL share price P/E of 58.20x and ROE of 37.93% against the industry averages to determine competitive standing.
What is the P/E ratio of JSLL and what does it mean?
JSLL share price has a P/E ratio of 58.20x compared to the industry average of 31.77x. Investors pay ₹58 for every ₹1 of annual earnings.
How is JSLL performing according to Bull Run's analysis?
JSLL has a Bull Run fundamental score of 60.8/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does JSLL belong to?
JSLL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Jeena Sikho Lifecare Limited share price.
What is Return on Equity (ROE) and why is it important for JSLL?
JSLL has an ROE of 37.93%, which indicates excellent management efficiency. ROE measures how efficiently Jeena Sikho Lifecare Limited generates profits from shareholders capital.
How is JSLL debt-to-equity ratio and what does it indicate?
JSLL has a debt-to-equity ratio of 0.30, which indicates conservative financing with low financial risk.
What is JSLL dividend yield and is it a good dividend stock?
JSLL offers a dividend yield of 0.15%, meaning you receive ₹0.15 annual dividend for every ₹100 invested in Jeena Sikho Lifecare Limited shares.
How has JSLL share price grown over the past 5 years?
JSLL has achieved 5-year growth rates of: Sales Growth 37.81%, Profit Growth 72.79%, and EPS Growth -35.51%.
What is the promoter holding in JSLL and why does it matter?
Promoters hold 63.61% of JSLL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Jeena Sikho Lifecare Limited.
What is JSLL market capitalisation category?
JSLL has a market capitalisation of ₹8959 crores, placing it in the Mid-cap category.
How volatile is JSLL stock?
JSLL has a beta of N/A. A beta > 1 suggests the Jeena Sikho Lifecare Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is JSLL operating profit margin trend?
JSLL has a 5-year average Operating Profit Margin (OPM) of 23.44%, indicating the company's operational efficiency.
How is JSLL quarterly performance?
Recent quarterly performance shows Jeena Sikho Lifecare Limited YoY Sales Growth of 70.05% and YoY Profit Growth of 134.85%.
What is the institutional holding pattern in JSLL?
JSLL has FII holding of 6.59% and DII holding of 0.15%. Significant institutional holding often suggests professional confidence in the Jeena Sikho Lifecare Limited stock.